Rapport Therapeutics, Inc.

RAPP

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
SEC CIK: 0002012593

SEC filings (opens in a new tab)

In the last 90 days, Rapport Therapeutics, Inc. insiders filed 0 open-market purchases and 9 sales; 160 institutions reported holding it in 13F filings for Q2 2026, worth $2.13B in total; no superinvestor holds it.

Q2 2024 vs. Q1 2024

How the institutions holding Rapport Therapeutics, Inc. changed between Q1 2024 and Q2 2024.

All holders in Q2 2024 All holders in Q1 2024

13F holders of RAPP: Q1 2024 compared with Q2 2024
Measure	Q1 2024	Q2 2024	Change
Holders	0	35	+35
Shares	0	25.6M	+25.6M
Value	$0	$593.4M	+$593.4M

New holders (35)

Institutions that held Rapport Therapeutics, Inc. at the end of Q2 2024 but not at the end of Q1 2024.

Institutions new to RAPP in Q2 2024
Institution	Shares	Value	% of portfolio
FMR LLC	4,983,351	$115.9M	0.01%
ARCH Venture Management, LLC	3,728,738	$86.7M	32.60%
Cormorant Asset Management, LP	2,940,283	$68.4M	3.98%
Capital International Investors	2,602,531	$60.5M	0.01%
Johnson & Johnson	2,498,051	$58.1M	14.50%
Sofinnova Investments, Inc.	1,951,562	$45.4M	2.86%
T. Rowe Price Investment Management, Inc.	1,535,151	$35.7M	0.02%
Price T Rowe Associates Inc	1,360,605	$31.6M	0.00%
Alliancebernstein L.P.	1,090,858	$25.4M	0.01%
Perceptive Advisors LLC	748,183	$17.4M	0.42%
Citadel Advisors LLC	592,458	$13.2M	0.01%
Artal Group S.A.	350,000	$8.14M	0.21%
Logos Global Management LP	208,910	$4.37M	0.50%
Woodline Partners LP	171,100	$3.98M	0.04%
Millennium Management LLC	116,782	$2.72M	0.00%
TD Asset Management Inc	101,522	$2.36M	0.00%
Manufacturers Life Insurance Company, The	75,516	$1.76M	0.00%
Vanguard Group Inc	70,000	$1.63M	0.00%
Norges Bank	70,000	$1.63M	0.00%
Saturn V Capital Management LLC	70,000	$1.63M	0.62%
Eventide Asset Management, LLC	50,000	$1.16M	0.02%
LMR Partners LLP	50,000	$1.16M	0.02%
Monashee Investment Management LLC	40,000	$930.4K	0.12%
Alyeska Investment Group, L.P.	34,731	$807.8K	0.00%
Soros Fund Management LLCSuperinvestorSoros Fund Management	30,000	$697.8K	0.02%
Acuta Capital Partners, LLC	20,000	$465.2K	0.39%
Squarepoint Ops LLC	16,345	$380.2K	0.00%
Two Sigma Investments, LP	13,000	$302.4K	0.00%
Balyasny Asset Management LLC	10,000	$232.6K	0.00%
Davidson Kempner Capital Management LP	10,000	$228.6K	0.00%
Barclays PLC	9,400	$218.6K	0.00%
Sandia Investment Management LP	5,000	$116.3K	0.15%
UBS Group AG	3,127	$72.7K	0.00%
Tidemark, LLC	1,088	$25.3K	0.01%
Royal Bank of Canada	225	$5.00K	0.00%

Sold out (0)

Institutions that held Rapport Therapeutics, Inc. at the end of Q1 2024 and filed for Q2 2024 without it.

None.